Last $2.45 USD
Change Today +0.06 / 2.51%
Volume 192.4K
AMRS On Other Exchanges
Symbol
Exchange
Frankfurt
As of 4:00 PM 03/5/15 All times are local (Market data is delayed by at least 15 minutes).

amyris inc (AMRS) Snapshot

Open
$2.35
Previous Close
$2.39
Day High
$2.47
Day Low
$2.35
52 Week High
03/5/14 - $5.25
52 Week Low
01/21/15 - $1.56
Market Cap
193.7M
Average Volume 10 Days
353.6K
EPS TTM
$-2.71
Shares Outstanding
79.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AMYRIS INC (AMRS)

amyris inc (AMRS) Related Businessweek News

No Related Businessweek News Found

amyris inc (AMRS) Details

Amyris, Inc., a renewable products company, provides various alternatives to a range of petroleum-sourced products for the specialty chemical and transportation fuel markets worldwide. It builds and applies its industrial synthetic biology platform to design microbes, primarily yeast, to convert plant-sourced sugars into renewable hydrocarbons. The company produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products. It also provides Biofene for specialty chemical applications and transportation fuels, such as diesel. In addition, the company is involved in the development, production, and commercialization of renewable base oils, as well as additives and lubricants for the automotive, industrial, and commercial lubricants markets; and offers natural oils and aroma chemicals for the flavors and fragrances market. It has a strategic partnership with Total for the production and commercialization of diesel and jet fuels. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was founded in 2003 and is headquartered in Emeryville, California.

amyris inc (AMRS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $550.0K
President of Research and Development
Total Annual Compensation: $358.8K
Compensation as of Fiscal Year 2013.

amyris inc (AMRS) Key Developments

Amyris, Inc. and Genome Compiler Corp. Enters Collaboration Agreement to Commercialize DNA Construction Software Services for the Pharma and Biotech Industries

Amyris, Inc. and Genome Compiler Corp. have entered into a collaboration agreement to integrate Amyris's automated lab services with Genome Compiler's online design tools and e-commerce platform to enable users to design and order DNA or other biological products seamlessly. This integration will provide a comprehensive solution from design to delivery of first-of-its-kind integrated DNA design and construction service, which promises to be more automated, less expensive, and more sophisticated than current offerings. Customers will benefit from Genome Compiler's software tools and Amyris's rich libraries of verified genetic parts, DNA construction and editing methods.

Amyris, Inc. Presents at Morgan Stanley MLP/Diversified Natural Gas, Utilities and Clean Tech Conference, Mar-05-2015

Amyris, Inc. Presents at Morgan Stanley MLP/Diversified Natural Gas, Utilities and Clean Tech Conference, Mar-05-2015 . Venue: The St. Regis, New York, New York, United States.

Amyris, Inc. Reports Consolidated Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Cash Flow Guidance for the First Quarter and Earnings Guidance for the Full Year of 2015; Reports Impairments for the Fourth Quarter Ended December 31, 2014

Amyris, Inc. reported consolidated unaudited earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported total product sales of $4,704,000 against $4,496,000 a year ago. Total revenues were $11,585,000 against $15,397,000 a year ago, a decrease of 25% driven mainly by timing of achievement of collaboration milestones and a government grant completed in 2013. Loss from operations was $27,445,000 against $25,056,000 a year ago. Income before income taxes and loss from investment in affiliate was $60,040,000 against loss before income taxes and loss from investment in affiliate of $139,343,000 a year ago. Net income before loss from investment in affiliate was $59,915,000 against net loss before loss from investment in affiliate of $139,449,000 a year ago. Net income attributable to company's common stockholders was $58,021,000 against net loss attributable to company's common stockholders of $139,421,000 a year ago. Net loss per share attributable to common stockholders, diluted was $0.21 against $1.83 a year ago. For the full year, the company reported total product sales of $23,439,000 against $15,808,000 a year ago. Total revenues were $43,274,000 against $41,119,000 a year ago. The increase was driven by an increase in product sales of nearly 50%, offset in part by a decline in revenue recognized from government grants. Loss from operations was $99,828,000 against $119,616,000 a year ago. Income before income taxes and loss from investment in affiliate was $5,572,000 against loss before income taxes and loss from investment in affiliate of $235,754,000 a year ago. Net income before loss from investment in affiliate was $5,077,000 against net loss before loss from investment in affiliate of $234,907,000 a year ago. Net income attributable to company's common stockholders was $2,286,000 against net loss attributable to company's common stockholders of $235,111,000 a year ago. Net loss per share attributable to common stockholders, diluted was $0.90 against $3.12 a year ago. Total capital expenditures for the year were approximately $5 million. The company provided cash flow guidance for the first quarter and earnings guidance for the full year of 2015. The company expects to achieve positive cash flow from operations in the first quarter of 2015. The company expects to achieve total revenues of about $100 million to $110 million for 2015 and capital expenditures of around $6 million to $8 million. For the fourth quarter ended December 31, 2014, the company reported impairment of intangible assets, was $3,035,000 or $0.04 per basic share.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AMRS:US $2.45 USD +0.06

AMRS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
American Power Group Corp $0.25 USD -0.035
China Clean Energy Inc $0.05 USD -0.022
Gevo Inc $0.26 USD +0.012
Green Energy Resources Inc $0.0000 USD 0.00
View Industry Companies
 

Industry Analysis

AMRS

Industry Average

Valuation AMRS Industry Range
Price/Earnings 100.0x
Price/Sales 4.4x
Price/Book NM Not Meaningful
Price/Cash Flow 82.6x
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AMYRIS INC, please visit www.amyris.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.